Statistics from Altmetric.com
Driven by the high prevalence of human papillomavirus and HIV (10.8%),1 early sexual debut, and high parity, Malawi ranks as the country with the second highest cervical cancer incidence (age-standardized rate of 72.9/100 000) and mortality (age-standardized rate of 54.5/100 000) worldwide.2 In response to this, the Malawian Ministry of Health started a Cervical Cancer Control program in 1999, which was scaled up to all Malawian districts by 2011. As a long-standing health partner in the HIV program in Malawi, ‘Médecins Sans Frontières’ decided to strengthen the Ministry of Health strategy by implementing a comprehensive onco-gynecological program in Southern Malawi in collaboration with the Ministry of Health and the College of Medicine.
The program encompasses all stages of cervical cancer disease course including immunization, screening, treatment, and palliative care.3 Médecins Sans Frontières is strengthening the onco-gynecological treatment capacity in a multimodal way in order to ensure a strong operational capacity and a target of sustainability. This logistic approach encompasses the building of dedicated onco-gynecological outpatient (Figure 1) and inpatient departments and an operating theater (Figure 2) within the tertiary care Queen Elizabeth Central Hospital (QECH) in Blantyre, as well as a referral pathway for eligible patients to undergo chemoradiation in neighboring countries since no radiotherapy is currently available in Malawi. A tailored approach has been developed in close collaboration with the Obstetrics/Gynecology and Oncological Department of QECH in accordance with their own experience in neoadjuvant chemotherapy treatment while Médecins Sans Frontières is organizing a new form of ‘on site’ fellowship through short rotations of gynecological oncologists to support national staff.
Our guidelines encompass International Federation of Gynaecology and Obstetrics (FIGO) 2018 ultrasound staging and upfront or post-neoadjuvant chemotherapy radical hysterectomy according to the Querleu–Morrow classification and European Society of Gynaecological Oncology (ESGO) stratification risk. Special attention is given to therapeutic patient education, social assessment, and support as poverty significantly decreases the likelihood that patients will adhere to treatment and follow-up.4 Resources should be balanced across prevention and treatment in order to maximize the influence on cancer incidence and mortality in support of the Ministry of Health capacities. Quality control is based on the implementation of a longitudinal database and an electronic medical record (Bahmni)5 in order to link screening, diagnosis, and treatment with survival data. Continuous assessment of this project will give us valuable real-world experience in treating solid tumors in a resource-limited context with the objective of building a ubiquitous cancer care strategy in low- and middle-income countries.
The sustainability of such a project faces three major challenges: resources, continuous assessment of quality, and medical education.
Médecins Sans Frontières donors, Prof. Denis Querleu.
Collaborators Denis Querleu, Jerome Blanchot.
Contributors CN, P-FD, LM, and GC supervised the project. P-FD wrote the manuscript with the support of GC and LM. SM and GC developed the clinical aspects. All the authors discussed and contributed to the final manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.